[EN] NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING [FR] NOUVEL AGENT DE CONTRASTE DESTINÉ À ÊTRE UTILISÉ DANS L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE
Photo-irradiation of α-halo carbonyl compounds: a novel synthesis of α-hydroxy- and α,α′-dihydroxyketones
摘要:
The reaction of g.-halo ketones (alpha-iodocycloalkanones, alpha-bromocycloalkanones, alpha-iodo-beta-alkoxy esters, and alpha-iodoacyclic-ketones) with irradiation under a high-pressure mercury lamp gave the corresponding alpha-hydroxyketones in good yields. For alpha-bromoketones, it was found that alpha-hydroxylation does not occur. However, alpha-bromoketones were convened into a-hydroxyketones in the presence of KI. In the case of alpha,alpha(1)-diiodo ketones, alpha,alpha(1)-dihydroxyketones, which up to now have scarcely been reported, were obtained. This reaction affords a new, clean and convenient synthetic method for alpha-hydroxy- and alpha,alpha(1)-dihydroxyketones. (C) 2005 Elsevier Ltd. All rights reserved.
[EN] SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME<br/>[FR] INHIBITEURS SÉLECTIFS DE L'INFLAMMASOME NLRP3
申请人:NODTHERA LTD
公开号:WO2019025467A1
公开(公告)日:2019-02-07
The present disclosure relates to compounds of Formula (I): (I); and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.
Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
申请人:IWAKI Yuki
公开号:US20110124695A1
公开(公告)日:2011-05-26
The present invention provides a compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein R
1
, R
2
, R
3
, R
4
, R
6
, A
1
, A
2
, X
1
, s and m are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.